Figure 2From: Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study Motesanib pharmacokinetic (PK) parameter estimates across cohorts. Individual (circles) and median (lines) values are shown by motesanib dose cohort for Cmax (A), AUC0—24 (B), and C24 (C) values after oral administration of motesanib in combination with 100 mg QD erlotinib and gemcitabine or 150 mg QD erlotinib alone on week 3. Data for all subjects who received the protocol-specified treatment are shown.Back to article page